WallStSmart

Aveanna Healthcare Holdings Inc (AVAH)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 2508% more annual revenue ($65.77B vs $2.52B). MRK leads profitability with a 13.6% profit margin vs 10.4%. AVAH trades at a lower P/E of 7.0x. AVAH earns a higher WallStSmart Score of 62/100 (C+).

AVAH

Buy

62

out of 100

Grade: C+

Growth: 8.7Profit: 7.5Value: 5.7Quality: 3.5
Piotroski: 4/9Altman Z: 0.95

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AVAHSignificantly Overvalued (-84.3%)

Margin of Safety

-84.3%

Fair Value

$4.33

Current Price

$8.48

$4.15 premium

UndervaluedFair: $4.33Overvalued
MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$128.66

$47.70 premium

UndervaluedFair: $80.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVAH4 strengths · Avg: 9.5/10
P/E RatioValuation
7.0x10/10

Attractively priced relative to earnings

Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

EPS GrowthGrowth
612.0%10/10

Earnings expanding 612.0% YoY

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

AVAH4 concerns · Avg: 2.0/10
Market CapQuality
$1.84B3/10

Smaller company, higher risk/reward

Free Cash FlowQuality
$-208,0002/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.952/10

Distress zone — elevated risk

Debt/EquityHealth
6.261/10

Elevated debt levels

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AVAH

The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 15.9% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AVAH

The primary concerns for AVAH are Market Cap, Free Cash Flow, Altman Z-Score. Debt-to-equity of 6.26 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

AVAH profiles as a growth stock while MRK is a value play — different risk/reward profiles.

AVAH carries more volatility with a beta of 1.93 — expect wider price swings.

AVAH is growing revenue faster at 15.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

AVAH scores higher overall (62/100 vs 50/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aveanna Healthcare Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?